[Form 4] Akero Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (AKRO), reported multiple transactions on 10/01/2025 under a Rule 10b5-1 plan. He acquired 12,500 stock options at an exercise price of $21.10 and exercised options that resulted in ownership of 82,482 common shares in total. On the same date he sold 12,500 common shares via a market sale at a weighted-average price of $21.10 (option acquisition) and separately sold 8,299 shares at a weighted-average price of $47.644 and 4,201 shares at a weighted-average price of $47.984. Following the reported transactions, he directly beneficially owned 196,898 shares. He also holds indirect interests of 20,000 shares each through three irrevocable trusts for his children, which he disclaims as beneficial ownership.

Positive

• Acquired 12,500 stock options at an exercise price of $21.10
• Direct beneficial ownership of 196,898 shares following transactions
• Indirect holdings of 60,000 shares held in irrevocable trusts for children

Negative

• Sold 8,299 shares at a weighted-average price of $47.644
• Sold 4,201 shares at a weighted-average price of $47.984

Insights

Insider Trading Analyst

Insider sold 12,500 shares and sold additional 12,500 via 10b5-1 on 10/01/2025.

The Report shows a mix of option activity and open-market sales executed under a Rule 10b5-1 trading plan dated 04/29/2025. The filing records acquisition of 12,500 options at an exercise price of $21.10 and multiple sales totaling 24,?00 shares across two weighted-average sale-price ranges: $46.94–$47.93 and $47.94–$48.22, summarized as weighted-average prices of $47.644 and $47.984.

Because transactions were effected under a pre-established plan, they are mechanically executed rather than necessarily reflecting new company-specific information; the filing discloses direct beneficial ownership of 196,898 shares after the trades and indirect holdings of 60,000 shares in three irrevocable trusts for his children.

Corporate Governance Specialist

Transactions include option vesting schedule and trust-held shares.

The option reported vests in 48 equal monthly installments beginning 12/08/2021, and the Form discloses the standard disclaimer that trust-held shares are not claimed as beneficially owned. The signature on the Form is dated 10/03/2025, confirming timely reporting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Young Jonathan

(Last) (First) (Middle)

C/O AKERO THERAPEUTICS, INC.

601 GATEWAY BOULEVARD, SUITE 350

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		M(1)		12,500	A	$21.1	209,398	D
Common Stock	10/01/2025		S(1)		8,299	D	$47.644(3)	201,099	D
Common Stock	10/01/2025		S(1)		4,201	D	$47.984(4)	196,898	D
Common Stock								20,000	I	By EA Irrevocable Trust(2)
Common Stock								20,000	I	By CM Irrevocable Trust(2)
Common Stock								20,000	I	By JL Irrevocable Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$21.1	10/01/2025		M(1)			12,500	(5)	12/07/2031	Common Stock	82,482	$0	44,982	D

Explanation of Responses:

1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025, previously adopted by the Reporting Person.

2. These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.94 to $47.93, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.

4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.94 to $48.22, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.

5. This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2021

	/s/ Jonathan Young	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AKRO COO Jonathan Young file on Form 4?

Jonathan Young reported option acquisition and open-market sales on 10/01/2025, filed on 10/03/2025.

How many shares does Jonathan Young directly own after the transactions?

He directly beneficially owns 196,898 common shares following the reported transactions.

What sales did the Form 4 disclose for AKRO?

The filing shows sales of 8,299 shares at a weighted-average price of $47.644 and 4,201 shares at $47.984 on 10/01/2025.

Were the transactions executed under a trading plan?

Yes. The transactions were effected pursuant to a Rule 10b5-1 trading plan dated 04/29/2025.

Does Jonathan Young have indirect holdings?

Yes. The Form reports 20,000 shares each held in three irrevocable trusts (60,000 total) for his children, which he disclaims as beneficial ownership.